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Background: To investigate the association of single-nucleotide polymorphisms (SNPs) in matrix metalloproteinases
(MMPs)-2, -3, and -9 and tissue inhibitor of metalloproteinase (TIMP)-2 with moyamoya disease (MMD). We conducted a
case-control study of MMD patients by assessing the prevalence of six SNPs of MMP-2 -1575G > A [rs243866], MMP-2
-1306C > T [rs243865], MMP-3 -1171 5a/6a [rs3025058], MMP-9 -1562C > T [rs3918242], MMP-9 Q279R [rs17576], and
TIMP-2 -418G > C [rs8179090].
Methods: Korean patients with MMD (n = 107, mean age, 20.9 ± 15.9 years; 66.4% female) and 243 healthy control
subjects (mean age, 23.0 ± 16.1 years; 56.8% female) were included. The subjects were divided into pediatric and adult
groups. The genotyping of six well-known SNPs (MMP-2 -1575G > A, MMP-2 -1306C > T, MMP-3 -1171 5a/6a, MMP-9
-1562C > T, MMP-9 Q279R, and TIMP-2 -418G > C) in MMP and TIMP genes was performed by polymerase chain
reaction-restriction fragment length polymorphism assays.
Results: A significantly higher frequency of the GC genotype for TIMP-2 -418 G > C was found in MMD patients. The
MMP-9 Q279R GA + AA genotype showed a protective effect for MMD. The GA/CC MMP-2 -1575/-1306 genotype was
significantly more prevalent in MMD patients.
Conclusions: Our findings demonstrate that TIMP-2 -418 GC + CC and MMP-2 -1575GA/-1306CC genotypes could be
genetic predisposing factors for MMD development.
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The presence of a G/C heterozygous genotype at pos-
ition -418 in the promoter of the tissue inhibitor of
metalloproteinase-2 (TIMP-2) gene has been proposed
as a genetic predisposing factor for moyamoya disease
(MMD) [1], but this association is debated [2]. It is not
clear whether there is a genetic effect or an influence of
arterial steno-occlusive disease [3]. Although the cause* Correspondence: dskim33@yuhs.ac; nkkim@cha.ac.kr
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unless otherwise stated.of MMD is still unknown, a genetic background has
been strongly suggested, and familial MMD (FMMD)
loci have been identified with linkage analyses, support-
ing a multifactorial inheritance pattern [4-7].
Several studies have demonstrated that overexpression
of matrix metalloproteinase-9 (MMP-9) and underexpres-
sion of MMP-3, TIMP-1, and TIMP-2 are related to MMD
[8,9]. Smooth muscle cells (SMC) produce both MMP-2
and-9, and a genetic deficiency in either may decrease
SMC invasion and the formation of intimal hyperplasia
[10], but no MMP genes are located in the loci known to
contain MMD genes [1]. TIMP dysregulation would dis-
rupt the balance between MMPs and TIMPs and result in
erroneous SMC dynamics, and this could subsequently. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Park et al. BMC Neurology 2014, 14:180 Page 2 of 8
http://www.biomedcentral.com/1471-2377/14/180facilitate MMD development [1]. These findings remain to
be confirmed in MMD patients. TIMP dysregulation can
disrupt the balance between MMPs and TIMPs, resulting
in aberrant SMC dynamics, ultimately leading to MMD
[1,2]. Therefore, any single-nucleotide polymorphisms
(SNPs) of proteins involved in this cascade may provoke
or protect against ischemic or hemorrhagic MMD. Shear
stress is very high at the location of proximal internal ca-
rotid artery, which might lead to intimal thickening in case
of genetic abnormality [11,12]. Dysregulation of MMPs 2,
3, 9 and their endogenous inhibitor TIMP-2 was is critical
for appropriate extracellular matrix remodeling in re-
sponse to shear stress in MMD [1,13-15]. MMD can
develop in the context of MMP or TIMP genetic suscepti-
bilities and hemodynamic stress. Therefore, we tested
whether SNPs of MMPs 2, 3, and 9 and TIMP-2 were as-
sociated with MMD in this study.
These genetic abnormalities could facilitate the break-
down of tissue remodeling during moyamoya vessel devel-
opment, ultimately leading to cerebral ischemia or
cerebral hemorrhage. MMD can develop among MMP or
TIMP genetic susceptibility against hemodynamic stress.
To test this hypothesis, we conducted a case-control
study of MMD patients by assessing the prevalence of six
SNPs of MMP-2, -3, -9 and TIMP-2 (MMP-2 -1575G >A
[rs243866], MMP-2 -1306C > T [rs243865], MMP-3 -1171
5a/6a [rs3025058], MMP-9 -1562C >T [rs3918242], MMP-
9 Q279R [rs17576], and TIMP-2 -418G >C [rs8179090]).
Methods
Subjects
A total of 107 consecutive Korean patients with MMD






<18 years 102 (42.0) 56 (52.3)
≥18 years 141 (58.0) 51 (47.7)
Age (means ± SD)
<18 years 7.71 ± 4.05 7.98 ± 4.13
≥18 years 36.72 ± 10.05 34.98 ± 11.29
Sex [male, n(%)]
<18 years 54 (52.9) 22 (39.3)
≥18 years 51 (21.0) 14 (27.5)




*P values were calculated using the Mann-Whitney test for continuous data and χ2-
†Fisher’s exact test. NA; not applicable.[33.6%]) were recruited for this study. MMD was defined
as the presence of clinical ischemic or hemorrhagic symp-
toms in combination with vascular lesion evidence on
magnetic resonance imaging (MRI) or magnetic resonance
angiography (MRA).
The control group was comprised of 243 healthy sub-
jects (mean age, 23.0 ± 16.1 years; 138 female [56.8%];
105 male [43.2%]) from the same geographic region as
the MMD patients. The age- and sex-matched subjects
were recruited from outpatient clinics at Severance Hos-
pital (Seoul, Korea) and CHA Bundang Medical Center
(Seongnam, Korea). They were healthy volunteers who
came in for their regular health examinations. Partici-
pants were encouraged to enroll this study, but no in-
centive as provided to aid recruitment. Control subjects
were not related to the participants but were healthy
volunteers who came in for their regular health exami-
nations at our university-based hospital.
MMD has a bimodal pattern of incidence, so we di-
vided the patients into pediatric (<18 years) and adult
(≥18 years) subgroups. We further divided the MMD pa-
tients into ischemic or hemorrhagic subgroups based on
clinical and MRI findings. We performed indirect bypass
surgery in 64 patients and direct superficial temporal ar-
tery to middle cerebral artery bypass plus encephalo-
duro-arterio-myo-synangiosis (STA-MCA plus EDAMS)
in one patient. Table 1 shows the demographic charac-
teristics of the MMD patients and control subjects.
All participants provided written informed consent prior
to study enrollment. The institutional review boards of
Severance Hospital (4-2008-0308) and CHA Bundang
Medical Center (PBC09-103,BD 2012-136D,BD 2012-






54 (58.7) 2 (13.3)
38 (41.3) 13 (86.7)
0.92 8.11 ± 4.12 4.50 ± 3.54 NA
0.25 34.63 ± 11.45 36.00 ± 11.21 0.69
0.10 21 (38.9) 1 (50.0) 1.00†
0.26 12 (31.6) 2 (15.4) 0.47†
test for categorical data.
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DNA was extracted from leukocytes using a G-DEX™ II
Genomic DNA Extraction kit (Intron Biotechnology,
Seongnam, Korea) according to the manufacturer’s
instructions.
For each of the SNPs, 30% of the polymerase chain re-
action (PCR) assays were randomly chosen for a secondTable 2 The genotype frequencies of MMP polymorphisms be
disease
Characteristic Control (n = 243) Moyamoya (n =
MMP2 -1575G > A (rs243866)
GG 210 (86.4) 92 (86.0)
GA 33 (13.6) 15 (14.0)
AA 0 (0.0) 0 (0.0)
Dominant (GG vs. GA + AA)
Recessive (GG + GA vs. AA)
HWE P 0.256 0.436
MMP2 -1306C > T (rs243865)
CC 222 (91.4) 99 (92.5)
CT 21 (8.6) 8 (7.5)
TT 0 (0.0) 0 (0.0)
Dominant (CC vs. CT + TT)
Recessive (CC + CT vs. TT)
HWE P 0.481 0.688
MMP3 -1171 5a/6a (rs3025058)
6a6a 187 (77.0) 78 (72.9)
6a5a 51 (21.0) 23 (21.5)
5a5a 5 (2.1) 6 (5.6)
Dominant (6a6a vs. 6a5a + 5a5a)
Recessive (6a6a + 6a5a vs. 5a5a)
HWE P 0.493 0.027
MMP9 -1562C > T (rs3918242)
CC 195 (80.2) 85 (79.4)
CT 47 (19.3) 19 (17.8)
TT 1 (0.4) 3 (2.8)
Dominant (CC vs. CT + TT)
Recessive (CC + CT vs. TT)
HWE P 0.298 0.149
MMP9 Q279R (rs17576)
GG 100 (41.2) 56 (52.3)
GA 120 (49.4) 46 (43.0)
AA 23 (9.5) 5 (4.7)
Dominant (GG vs. GA + AA)
Recessive (GG + GA vs. AA)
HWE P 0.127 0.244
Adjusted by age and gender. NA; Not applicable.
aP value obtained by Fisher’s exact test.
bFalse positive discovery rate-adjusted P value.PCR assay followed by DNA sequencing to validate the
restriction fragment length polymorphism RFLP find-
ings. Sequencing was performed using an ABI3730xl
DNA Analyzer (Applied Biosystems, Foster City, CA,
USA). The concordance of the quality control samples
was 100%. Each of genotyping methods are described in
detail in the Additional file 1.tween the control group and patients with moyamoya
107) AOR (95% CI) Pa Pb
1.00 (reference)
1.03 (0.53-2.00) 0.94 0.94
NA NA
1.03 (0.53-2.00) 0.94 0.94
NA NA
1.00 (reference)
0.87 (0.37-2.05) 0.75 0.75
NA NA
0.87 (0.37-2.05) 0.75 0.75
NA NA
1.00 (reference)
1.07 (0.61-1.89) 0.81 0.81
2.92 (0.85-10.00) 0.09 0.18
1.24 (0.74-2.10) 0.42 0.56
3.00 (0.88-10.20) 0.08 0.18
1.000 (reference)
0.91 (0.50-1.66) 0.76 0.92
6.12 (0.62-60.42) 0.12 0.24
1.03 (0.58-1.83) 0.92 0.92
6.45 (0.65-63.68) 0.11 0.24
1.000 (reference)
0.66 (0.41-1.07) 0.09 0.11
0.36 (0.13-1.00) 0.05 0.10
0.61 (0.39-0.98) 0.04 0.10
0.45 (0.16-1.22) 0.11 0.11
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To analyze the demographic characteristics of MMD, we
performed Mann–Whitney U tests and chi-square (χ2)
tests for continuous and categorical data, respectively.
The associations among pediatric and adult patients
were estimated by computing the odds ratios (ORs) and
95% confidence intervals (CIs) using Fisher’s exact tests.
The adjusted ORs (AORs) for MMP and TIMP SNPs
were calculated using multiple logistic regression ana-
lyses using sex and age. Deviations of genotype propor-
tions from Hardy-Weinberg equilibrium (HWE) were






AOR (95% CI) Pa
MMP-2 -1575G > A
GG 88 (86.3) 46 (82.1) 1.00 (reference)
GA 14 (13.7) 10 (17.9) 1.32 (0.54-3.23) 0.5
AA 0 (0.0) 0 (0.0) NA NA
Dominant (GG vs. GA + AA) 1.32 (0.54-3.23) 0.5
Recessive (GG + GA vs. AA) NA NA
MMP-2 -1306C > T
CC 90 (88.2) 53 (94.6) 1.00 (reference)
CT 12 (11.8) 3 (5.4) 0.44 (0.12-1.65) 0.2
TT 0 (0.0) 0 (0.0) NA NA
Dominant (CC vs. CT + TT) 0.44 (0.12-1.65) 0.2
Recessive (CC + CT vs. TT) NA NA
MMP-3 -1171 5a/6a
6a6a 76 (74.5) 43 (76.8) 1.000 (reference)
6a5a 24 (23.5) 10 (17.9) 0.73 (0.32-1.69) 0.4
5a5a 2 (2.0) 3 (5.4) 3.03 (0.47-19.31) 0.2
Dominant (6a6a vs. 6a5a + 5a5a) 0.90 (0.42-1.95) 0.8
Recessive (6a6a + 6a5a vs. 5a5a) 3.55 (0.56-22.60) 0.1
MMP-9 -1562C > T
CC 79 (77.5) 45 (80.4) 1.00 (reference)
CT 22 (21.6) 9 (16.1) 0.62 (0.257-1.493) 0.2
TT 1 (1.0) 2 (3.6) 3.79 (0.33-43.80) 0.2
Dominant (CC vs. CT + TT) 0.75 (0.33-1.71) 0.4
Recessive (CC + CT vs. TT) 4.24 (0.37-48.86) 0.2
MMP-9 Q279R
GG 41 (40.2) 29 (51.8) 1.000 (reference)
GA 52 (51.0) 25 (44.6) 0.70 (0.35-1.38) 0.3
AA 9 (8.8) 2 (3.6) 0.25 (0.05-1.29) 0.1
Dominant (GG vs. GA + AA) 0.63 (0.32-1.24) 0.1
Recessive (GG + GA vs. AA) 0.38 (0.08-1.83) 0.2
Adjusted by age and gender. NA; Not applicable.
aP value obtained by Fisher’s exact test.
bFalse positive discovery rate-adjusted P value.We marked reference group in tables. The usual type for
each locus was chosen as the reference group. Regres-
sion coefficient of statistically significant model in detail
in the Additional file 2. Statistical analyses were per-
formed using GraphPad Prism 4.0 (GraphPad Software,
Inc., San Diego, CA, USA) and StatsDirect software (ver-
sion 2.4.4; StatsDirect Ltd., Altrincham, UK).
Results
Table 1 compares the demographic characteristics be-
tween controls and MMD patients. The genetic distribu-






AOR (95% CI) Pa Pb
122 (86.5) 46 (90.2) 1.00 (reference)
5 0.55 19 (13.5) 5 (9.8) 0.73 (0.26-2.08) 0.56 0.56
0 (0.0) 0 (0.0) NA NA
5 0.55 0.73 (0.26-2.08) 0.56 0.56
NA NA
132 (93.6) 46 (90.2) 1.00 (reference)
2 0.22 9 (6.4) 5 (9.8) 1.63 (0.51-5.17) 0.41 0.41
0 (0.0) 0 (0.0) NA NA
2 0.22 1.63 (0.51-5.17) 0.41 0.41
NA NA
111 (78.7) 35 (68.6) 1.00 (reference)
6 0.61 27 (19.1) 13 (25.5) 1.52 (0.71-3.27) 0.28 0.28
4 0.48 3 (2.1) 3 (5.9) 3.17 (0.61-16.45) 0.17 0.28
0 0.80 1.69 (0.82-3.46) 0.15 0.28
8 0.48 2.89 (0.56-14.94) 0.21 0.28
116 (82.3) 40 (78.4) 1.00 (reference)
9 0.39 25 (17.7) 10 (19.6) 1.22 (0.54-2.79) 0.63 0.63
9 0.39 0 (0.0) 1 (2.0) NA NA
9 0.49 1.34 (0.60-3.00) 0.47 0.63
5 0.39 NA NA
59 (41.8) 27 (52.9) 1.00 (reference)
0 0.30 68 (48.2) 21 (41.2) 0.65 (0.33-1.29) 0.22 0.29
0 0.30 14 (9.9) 3 (5.9) 0.41 (0.10-1.60) 0.20 0.29
9 0.30 0.62 (0.32-1.18) 0.15 0.29
3 0.30 0.52 (0.14-1.92) 0.33 0.33
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http://www.biomedcentral.com/1471-2377/14/180Among these, the dominant type (GG vs. GA + AA) of
MMP-9 Q279R (rs17576) was significantly different by
χ2 test but not by false-positive discovery rate-adjusted
p-value (Table 2). The genetic distributions of MMP-2
-1575 G > A, MMP-2 -1306 C > T, and MMP-3-1171 5a/
6a were not significantly different between control and
MMD. Table 3 shows the genotype frequencies of MMP
SNPs between the control group and patients with
MMD according to age. There was no age-specific
differences among the MMP-2 -1575G > A (rs243866),
MMP-2 -1306C > T (rs243865), MMP-3 -1171 5a/6a
(rs3025058), MMP-9 -1562C > T (rs3918242), or MMP-9
Q279R (rs17576) genotypes (Table 3).
In Table 4, the GA/CC-combined genotype of MMP-2
-1575/-1306 was significantly different in the pediatric
group (Table 4). The GC sequence of TIMP-2 -418
(rs8179090) was significantly different from control
(Table 5). The dominant (GG vs. GC + CC) genotype of
TIMP-2 -418 was more frequent in patients with MMD.
In the subgroup analysis shown in Table 6, the GC se-
quence of TIMP-2 -418 (rs8179090) was significantly






AOR (95% CI) Pa
MMP-2 -1575/-1306
GG/CC 88 (86.3) 46 (82.1) 1.00 (reference)
GG/CT 0 (0.0) 0 (0.0) NA NA
GG/TT 0 (0.0) 0 (0.0) NA NA
GA/CC 2 (2.0) 7 (12.5) 6.70 (1.34-33.60) 0.01
GA/CT 12 (11.8) 3 (5.4) 0.48 (0.13-1.78) 0.39
GA/TT 0 (0.0) 0 (0.0) NA NA
AA/CC 0 (0.0) 0 (0.0) NA NA
AA/CT 0 (0.0) 0 (0.0) NA NA
AA/TT 0 (0.0) 0 (0.0) NA NA
MMP-9 -1562/Q279R
CC/GG 25 (24.8) 22 (39.3) 1.00 (reference)
CC/GA 45 (44.1) 21 (37.5) 0.53 (0.24-1.16) 0.11
CC/AA 9 (8.8) 2 (3.6) 0.24 (0.05-1.25) 0.09
CT/GG 15 (14.7) 5 (8.9) 0.50 (0.15-1.71) 0.27
CT/GA 7 (6.9) 4 (7.1) 0.59 (0.14-2.43) 0.46
CT/AA 0 (0.0) 0 (0.0) NA NA
TT/GG 1 (1.0) 2 (3.6) 3.73 (0.24-58.01) 0.35
TT/GA 0 (0.0) 0 (0.0) NA NA
TT/AA 0 (0.0) 0 (0.0) NA NA
Adjusted by age and gender. NA; Not applicable.
aP value obtained by Fisher’s exact test.
bFalse positive discovery rate-adjusted P value.(GG vs. GC + CC) genotype was more common in adult
MMD patients.
Genetic impairment of TIMP-2 and MMP-2 related
with MMD vascular repair gene. We found an abnormal-
ity in the GA/CC combined genetic sequence in MMP-2
-1575/-1306 and the GC sequence of TIMP-2 -418
(rs8179090), as well as the dominant type (GG vs. GC +
CC) in MMD.
Discussion
In this study, we found that the presence of a G/C het-
erozygous genotype at position -418 in the TIMP-2
(rs8179090) promoter, MMP-2 -1575GA/-1306CC, and
the dominant type (GG vs. GA + AA) of MMP-9 Q279R
(rs17576) could be genetic predisposing factors for MMD.
By degrading the neurovascular matrix, MMPs promote
blood-brain barrier (BBB) damage, edema, and hemor-
rhage [13,16,17]. Several studies have demonstrated that
overexpression of MMP-9 and underexpression of MMP-
3, TIMP-1, and TIMP-2 are related to MMD [8,9].
The balance between MMPs and TIMPs is known to






AOR (95% CI) Pa Pb
122 (86.5) 46 (90.2) 1.00 (reference)
0 (0.0) 0 (0.0) NA NA
0 (0.0) 0 (0.0) NA NA
0.02 10 (7.1) 0 (0.0) 0.13 (0.01-2.19) 0.07 0.14
0.39 9 (6.4) 5 (9.8) 1.47 (0.47-4.63) 0.54 0.54
0 (0.0) 0 (0.0) NA NA
0 (0.0) 0 (0.0) NA NA
0 (0.0) 0 (0.0) NA NA
0 (0.0) 0 (0.0) NA NA
45 (31.9) 19 (37.3) 1.00 (reference)
0.28 57 (40.4) 18 (35.3) 0.72 (0.34-1.55) 0.40 0.62
0.28 14 (9.9) 3 (5.9) 0.44 (0.11-1.76) 0.25 0.62
0.44 14 (9.9) 7 (13.7) 1.32 (0.45-3.91) 0.62 0.62
0.46 11 (7.8) 3 (5.9) 0.66 (0.16-2.66) 0.56 0.62
0 (0.0) 0 (0.0) NA NA
0.44 0 (0.0) 1 (2.0) NA NA
0 (0.0) 0 (0.0) NA NA
0 (0.0) 0 (0.0) NA NA






AOR (95% CI) Pa Pb
TIMP-2 -418G > C (rs8179090)
GG 178 (73.3) 56 (52.3) 1.00 (reference)
GC 61 (25.1) 46 (43.0) 2.33 (1.42-3.80) <.01 0.02
CC 4 (1.6) 5 (4.7) 3.53 (0.89-13.98) 0.07 0.09
Dominant (GG vs. GC + CC) 2.39 (1.48-3.85) <.01 0.02
Recessive (GG + GC vs. CC) 2.32 (0.60-8.96) 0.23 0.23
HWE P 0.64 0.24
Adjusted by age and gender. NA; Not applicable.
aP value obtained by Fisher’s exact test.
bFalse positive discovery rate-adjusted P value.
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http://www.biomedcentral.com/1471-2377/14/180angiogenesis [18]. MMP-2 and -9 are able to digest the
endothelial basal lamina, which plays a major role in
maintaining BBB impermeability by regulating tight
junctions leading to the opening of BBB [19]. MMP-2
and MMP-9 released from the vascular endothelium and
leukocytes during the inflammatory phase of ischemic
stroke use collagen IV and laminin as substrates [20,21].
Serum MMP-9 levels were significantly higher in pa-
tients with MMD compared to that in healthy controls
[8,9]. It is conceivable that MMP-9 upregulation may con-
tribute, at least in part, to the breakdown of BBB structure,
including endothelial basal lamina, and thereby facilitate
hemorrhage development [9,22]. Any genetic abnormality
or hemodynamic stress raises the possibility of BBB break-
down in patients with predisposing MMP or TIMP gene
susceptibility. MMD can develop among MMP or TIMP
genetic susceptibility against hemodynamic stress.
Several SNPs in the promoters of MMP genes have
been demonstrated to affect the expression levels of cor-
responding proteins [23-26]. Allelic effects on transcrip-
tional activity have also been demonstrated for MMP-2
C–735 T, MMP-3 –1171 5a/6a, and MMP-13G–77A
SNPs [25,27,28]. MMP-3 can degrade a number of ECM
proteins and activate several other MMPs, the 6a allelic






AOR (95% CI) Pa
TIMP2 -418G > C
GG 66 (64.7) 29 (51.8) 1.00 (reference)
GC 31 (30.4) 23 (41.1) 1.69 (0.84-3.42) 0.14
CC 5 (4.9) 4 (7.1) 1.91 (0.47-7.75) 0.37
Dominant 1.69 (0.86-3.29) 0.13
Recessive 1.36 (0.34-5.38) 0.67
Adjusted by age and gender. NA; Not applicable.
aP value obtained by Fisher’s exact test.
bFalse positive discovery rate-adjusted P value.promoter exhibits lower promoter and transcriptional
activity than the 5a allele [25], and homozygosity of the
6a allele was associated with common carotid geometry
and carotid artery atherosclerosis [29,30].
Here, we investigated five SNPs in MMPs and one
SNP in TIMP. Previous studies have reported associa-
tions between MMD and expression levels of MMPs and
TIMPs [8,9]. TIMPs are the most important endogenous
inhibitors of MMPs, in particular TIMP-1 and TIMP-2.
Therefore, SNPs that lead to structural defects or modify
the transcription rate of TIMP-2 could affect BBB break-
down and thereby influence the magnitude and/or inci-
dence of ischemic stroke and intracranial hemorrhage [31].
SNPs can also interfere with the balance of MMPs and
TIMP-2 in the absence of acute BBB disruption, thereby
influencing the development and severity of atheroscler-
osis, white matter lesions, and small-vessel disease [31].
While TIMP-2 has already been demonstrated to play a
role in MMD, it is important to replicate and support previ-
ous studies. Our results corroborate previous FMMD stud-
ies by Kang et al [1], but are different from those reported
by other groups [14,15]. The discrepancy might be due to
different genetic backgrounds among patient populations.
The major strength of this study is that we were able to






AOR (95% CI) Pa Pb
110 (78.0) 27 (52.9) 1.00 (reference)
0.28 31 (22.0) 23 (45.1) 2.99 (1.49-5.98) <.01 0.01
0.49 0 1 (2.0) NA NA
0.28 3.10 (1.56-6.18) <.01 0.01
0.67 NA NA
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Our findings provide additional evidence that the G/C
genotype -418 of TIMP-2 is more prevalent in individuals
with MMD.
Potential weaknesses of this study are that the sample
did not include patients with familial MMD, and family
pedigrees were not assessed. Also, as this was an associ-
ation study with a case-control study design, independ-
ent cohort studies are needed to confirm our findings.
We did not perform a correlation study with blood MMP
and TIMP levels. We selected only a few MMP and TIMP
candidate SNPs; therefore, more genetic sequences would
be needed to reach stronger conclusions. In addition, the
small sample size may have resulted in a Type I error. The
inconsistency between the family- and population-based
studies could be due to various reasons, and more com-
pelling evidence is needed to clarify this.
Conclusions
Our findings demonstrate that the G/C heterozygous
genotype in the TIMP-2-418G>C (rs8179090) promoter,
MMP-2 -1575GA/-1306CC, and the dominant type (GG
vs. GA+AA) of MMP-9 Q279R (rs17576) could be gen-
etic predisposing factors for MMD development. These
genetic polymorphisms can lead to the breakdown of tis-
sue remodeling during MMD progression, which could
lead to cerebral ischemia or cerebral hemorrhage. These
results are consistent with previous studies of the genetic
dysregulation of vascular repair mechanisms.
Additional files
Additional file 1: Genotyping.
Additional file 2: Table S1. Regression coefficient of statistically
significant models.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: YSP, DSK, and NKK. Performed the
experiments: YJJ and HSK. Analyzed the data: YSP, YJJ, and NKK. Contributed
reagents/materials/analysis tools: SHO, IBH, HSK, DSK, and NKK. Wrote the
paper: YSP, YJJ, and NKK. All authors read and approved the final manuscript.
Acknowledgments
This work was supported by the National Research Foundation of Korea
(2013R1A2A2A01067990) and by the research grant of the Chungbuk
National University in 2013.
Author details
1Department of Neurosurgery, Chungbuk National University, College of
Medicine, Cheongju-si, South Korea. 2Institute for Clinical Research, CHA
University School of Medicine, Seongnam, South Korea. 3Department of
Neurology, CHA Bundang Medical Center, CHA University School of
Medicine, Seongnam, South Korea. 4Department of Pediatric Neurosurgery,
Severance Hospital, Brain Korea 21 Project for Medical Science, Brain
Research Institute, Yonsei University College of Medicine, Seoul, Korea.Received: 6 March 2014 Accepted: 10 September 2014References
1. Kang HS, Kim SK, Cho BK, Kim YY, Hwang YS, Wang KC: Single nucleotide
polymorphisms of tissue inhibitor of metalloproteinase genes in familial
moyamoya disease. Neurosurgery 2006, 58:1074–1080. discussion 1074-1080.
2. Andreone V, Scala S, Tucci C, Di Napoli D, Linfante I, Tessitore A, Faiella A:
Single nucleotide polymorphisms of tissue inhibitors of
metalloproteinase genes in familial moyamoya disease. Neurosurgery
2008, 62:E1384. author reply E1384.
3. Yilmaz EY, Pritz MB, Bruno A, Lopez-Yunez A, Biller J: Moyamoya: Indiana
University Medical Center experience. Arch Neurol 2001, 58:1274–1278.
4. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T: Mapping of a familial
moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet
1999, 64:533–537.
5. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M: Linkage analysis of
moyamoya disease on chromosome 6. J Child Neurol 2000, 15:179–182.
6. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, Arinami T: A
novel susceptibility locus for moyamoya disease on chromosome 8q23.
J Hum Genet 2004, 49:278–281.
7. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H,
Inoue T, Ikezaki K, Matsushima T, Fukui M: Linkage of familial moyamoya
disease (spontaneous occlusion of the circle of Willis) to chromosome
17q25. Stroke 2000, 31:930–935.
8. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK: Plasma
matrix metalloproteinases, cytokines and angiogenic factors in
moyamoya disease. J Neurol Neurosurg Psychiatry 2010, 81:673–678.
9. Fujimura M, Watanabe M, Narisawa A, Shimizu H, Tominaga T: Increased
expression of serum Matrix Metalloproteinase-9 in patients with
moyamoya disease. Surg Neurol 2009, 72:476–480. discussion 480.
10. Johnson C, Galis ZS: Matrix metalloproteinase-2 and -9 differentially
regulate smooth muscle cell migration and cell-mediated collagen
organization. Arterioscler Thromb Vasc Biol 2004, 24:54–60.
11. Paszkowiak JJ, Dardik A: Arterial wall shear stress: observations from the
bench to the bedside. Vasc Endovascular Surg 2003, 37:47–57.
12. Roder C, Nayak NR, Khan N, Tatagiba M, Inoue I, Krischek B: Genetics of
Moyamoya disease. J Hum Genet 2010, 55:711–716.
13. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH:
Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis
of blood-brain barrier and white matter components after cerebral
ischemia. J Neurosci 2001, 21:7724–7732.
14. Li H, Zhang ZS, Liu W, Yang WZ, Dong ZN, Ma MJ, Han C, Yang H, Cao WC,
Duan L: Association of a functional polymorphism in the MMP-3 gene
with Moyamoya Disease in the Chinese Han population. Cerebrovasc Dis
2010, 30:618–625.
15. Paez MT, Yamamoto T: Single nucleotide polymorphisms of tissue
inhibitor of metalloproteinase genes in familial moyamoya disease.
Neurosurgery 2007, 60:E582. author reply E582.
16. Lo EH, Dalkara T, Moskowitz MA: Mechanisms, challenges and
opportunities in stroke. Nat Rev Neurosci 2003, 4:399–415.
17. Lee SR, Lo EH: Induction of caspase-mediated cell death by matrix
metalloproteinases in cerebral endothelial cells after hypoxia-reoxygenation.
J Cereb Blood Flow Metab 2004, 24:720–727.
18. Lee CZ, Xu B, Hashimoto T, McCulloch CE, Yang GY, Young WL: Doxycycline
suppresses cerebral matrix metalloproteinase-9 and angiogenesis
induced by focal hyperstimulation of vascular endothelial growth factor
in a mouse model. Stroke 2004, 35:1715–1719.
19. Rosenberg GA, Navratil M: Metalloproteinase inhibition blocks edema in
intracerebral hemorrhage in the rat. Neurology 1997, 48:921–926.
20. Hamann GF, del Zoppo GJ, von Kummer R: Hemorrhagic transformation of
cerebral infarction–possible mechanisms. Thromb Haemost 1999,
82(Suppl 1):92–94.
21. Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix
metalloproteinase expression increases after cerebral focal ischemia in
rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke
1998, 29:1020–1030.
22. Wu G, Shi J, Wang F, Wang L, Feng A, Ren S: Effects of minimally invasive
procedures for evacuation of intracerebral hematoma in early stages on
MMP-9 and BBB permeability in rabbits. BMC Neurol 2014, 14:85.
Park et al. BMC Neurology 2014, 14:180 Page 8 of 8
http://www.biomedcentral.com/1471-2377/14/18023. Price SJ, Greaves DR, Watkins H: Identification of novel, functional genetic
variants in the human matrix metalloproteinase-2 gene: role of Sp1 in
allele-specific transcriptional regulation. J Biol Chem 2001, 276:7549–7558.
24. Ye S: Polymorphism in matrix metalloproteinase gene promoters:
implication in regulation of gene expression and susceptibility of various
diseases. Matrix Biol 2000, 19:623–629.
25. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM:
Progression of coronary atherosclerosis is associated with a common
genetic variant of the human stromelysin-1 promoter which results in
reduced gene expression. J Biol Chem 1996, 271:13055–13060.
26. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D,
Luc G, Cambien F, Hamsten A, Watkins H, Henney AM: Functional
polymorphism in the regulatory region of gelatinase B gene in relation
to severity of coronary atherosclerosis. Circulation 1999, 99:1788–1794.
27. Yoon S, Kuivaniemi H, Gatalica Z, Olson JM, Buttice G, Ye S, Norris BA,
Malcom GT, Strong JP, Tromp G: MMP13 promoter polymorphism is
associated with atherosclerosis in the abdominal aorta of young black
males. Matrix Biol 2002, 21:487–498.
28. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D: Functional haplotypes in the
promoter of matrix metalloproteinase-2 predict risk of the occurrence
and metastasis of esophageal cancer. Cancer Res 2004, 64:7622–7628.
29. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM,
Bouchard C, Toyry J, Humphries SE: Stromelysin-1 and interleukin-6 gene
promoter polymorphisms are determinants of asymptomatic carotid
artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2657–2662.
30. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud
R, Mattioli PL, Federici G, Cortese C: Genetic variation in human
stromelysin gene promoter and common carotid geometry in healthy
male subjects. Arterioscler Thromb Vasc Biol 2000, 20:1600–1605.
31. Reuter B, Bugert P, Stroick M, Bukow S, Griebe M, Hennerici MG, Fatar M:
TIMP-2 gene polymorphism is associated with intracerebral hemorrhage.
Cerebrovasc Dis 2009, 28:558–563.
doi:10.1186/s12883-014-0180-5
Cite this article as: Park et al.: The GC + CC genotype at position -418 in
TIMP-2 promoter and the -1575GA/-1306CC genotype in MMP-2 is
genetic predisposing factors for prevalence of moyamoya disease. BMC
Neurology 2014 14:180.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
